Literature DB >> 21914486

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Sergio T Ferreira1, William L Klein.   

Abstract

Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21914486      PMCID: PMC4390395          DOI: 10.1016/j.nlm.2011.08.003

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  271 in total

Review 1.  Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.

Authors:  J J M Hoozemans; R Veerhuis; J M Rozemuller; P Eikelenboom
Journal:  Int J Dev Neurosci       Date:  2005-12-27       Impact factor: 2.457

2.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.

Authors:  Ming Tong; Alexander Neusner; Lisa Longato; Margot Lawton; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology.

Authors:  H Lin; R Bhatia; R Lal
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

6.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

7.  Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3.

Authors:  Alexandre Fifre; Isabelle Sponne; Violette Koziel; Badreddine Kriem; Frances T Yen Potin; Bernard E Bihain; Jean-Luc Olivier; Thierry Oster; Thierry Pillot
Journal:  J Biol Chem       Date:  2005-10-18       Impact factor: 5.157

8.  Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway.

Authors:  Cheng-Che Lee; Chiung-Chun Huang; Mei-Ying Wu; Kuei-Sen Hsu
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

9.  Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.

Authors:  Yukiko Doi; Tetsuya Mizuno; Yuki Maki; Shijie Jin; Hiroyuki Mizoguchi; Masayoshi Ikeyama; Minoru Doi; Makoto Michikawa; Hideyuki Takeuchi; Akio Suzumura
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

10.  Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany.

Authors:  Pablo Toro; Peter Schönknecht; Johannes Schröder
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more
  162 in total

Review 1.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

Review 2.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 3.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

4.  Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.

Authors:  Maria Clara Selles; Juliana T S Fortuna; Maria F Zappa-Villar; Yasmin P R de Faria; Amanda S Souza; Claudia K Suemoto; Renata E P Leite; Roberta D Rodriguez; Lea T Grinberg; Paula C Reggiani; Sergio T Ferreira
Journal:  Mol Neurobiol       Date:  2019-11-23       Impact factor: 5.590

5.  Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.

Authors:  L Devi; M Ohno
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

6.  Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.

Authors:  Leonie H E Leithold; Nan Jiang; Julia Post; Tamar Ziehm; Elena Schartmann; Janine Kutzsche; N Jon Shah; Jörg Breitkreutz; Karl-Josef Langen; Antje Willuweit; Dieter Willbold
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

Review 7.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 8.  A Mitocentric View of Alzheimer's Disease.

Authors:  Hao Hu; Chen-Chen Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-10-01       Impact factor: 5.590

9.  Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology.

Authors:  M Moon; H Song; H J Hong; D W Nam; M-Y Cha; M S Oh; J Yu; H Ryu; I Mook-Jung
Journal:  Cell Death Differ       Date:  2012-12-21       Impact factor: 15.828

Review 10.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.